Also, in breast cancer, IGFBP‐2 exerts malignant potential, and again, this depends on the RGD‐motif but involves regulation of estrogen receptors as demonstrated by the Perks laboratory (Foulstone et al., 2013). Here, ESR1 is linked to breast cancer.